2 Cardiovascular System - Plymouth Area Joint Formulary

• Home
• Chapters
  • 1. Gastro–Intestinal System
  • 2. Cardiovascular System
  • 3. Respiratory System
  • 4. Central Nervous System
  • 5. Infections
  • 6. Endocrine System
  • 7. Obstetrics, Gynaecology and Urinary–tract Disorders
  • 8. Malignant Disease and Immunossuppression
  • 9. Nutrition and Blood
  • 10. Musculoskeletal and Joint Diseases
  • 11. Eye
  • 12. Ear, Nose and Oropharynx
  • 13. Skin
  • 14. Immunological Products and Vaccines
  • 15. Anaesthesia
  • 16. Palliative Care Guidelines
  • 17 Wound Management
  • 18. Dental Prescribing
  • 19. Miscellaneous Preparations
  • 20. Shared Care Information
  • 21. Continence Formulary
• Drugs
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z
• About the Formulary and Local Decisions
  • Local Decisions about Drugs and Treatments
  • SW Peninsula Health Technology Commissioning Group
  • Joint Formulary Committee
  • Producing a Joint Formulary
  • Shared care Information
  • PHNT Drugs & Therapeutics Committee Minutes
• Newsletters
• Current Chapter Reviews
• Patient Information Leaflets
• General Prescribing Info
• GP System Formulary Downloads
• Useful Links
• Contact Us

2. Cardiovascular System

• 2.1.1 Cardiac glycosides
• 2.1.2 Phosphodiesterase inhibitors
• 2.2.1 Thiazide and related diuretics
• 2.2.2 Loop diuretics
• 2.2.3 Potassium–sparing diuretics
• 2.2.4 Potassium–sparing diuretics with other diuretics
• 2.2.5 Osmotic diuretics
• 2.3.2 Drugs for arrhythmias
• 2.4 Beta–adrenoceptor blocking drugs
• 2.5.1 Vasodilator antihypertensive drugs
• 2.5.2 Centrally acting antihypertensive drugs
• 2.5.4 Alpha–adrenoreceptor blocking drugs
• 2.5.5 Drugs affecting the renin–angiotensin system
• 2.6.1 Nitrates
• 2.6.2 Calcium–channel blockers
• 2.6.3 Other antianginal drugs
• 2.6.4 Peripheral and cerebral vasodilators
• 2.7.1 Inotropic sympathomimetics
• 2.7.2 Vasoconstrictor sympathomimetics
• 2.7.3 Cardiopulmonary resuscitation
• 2.8.1 Parenteral anticoagulants
• 2.8.2 Oral anticoagulants
• 2.8.3 Protamine sulphate
• 2.9 Antiplatelet drugs
• 2.10.2 Fibrinolytic drugs
• 2.11 Antifibrinolytic drugs and haemostatics
• 2.12 Lipid–lowering drugs
• 2.13 Local sclerosants

Appendices

• Appendix 01 Management of stable angina
• Appendix 02 Guideline Chronic heart failure
• Appendix 03 Secondary prevention of stroke TIA
• Appendix 04 Atrial Fibrillation
• Appendix 05 Peninsula Cardiac Network Guidance on New Anticoagulants
• Appendix 06 Guidance for clopidogrel (plus aspirin) in patients with coronary artery disease
• Appendix 07 Management of hypertension in adults in primary care
• Appendix 08 Adult Oral Anticoagulation Guidance
• Appendix 09 Slow Induction of Anticoagulation
• Appendix 10 Management of blood lipids
• Appendix 11 VTE Guidelines in Orthopaedics Trauma
• Appendix 12 Rivaroxaban DVT PE Factsheet

Last updated by: Carol Webb on 26-05-2011 16:58